Treatment with immune-checkpoint inhibitors (ICIs) against programmed death protein 1 and programmed death-ligand 1 (PD-L1) have revolutionized therapy of patients with advanced non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.